- Home
- MCRB
as 06-20-2025 3:38pm EST
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 72.0M | IPO Year: | 2015 |
| Target Price: | $73.67 | AVG Volume (30 days): | 74.1K |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 8.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.53 - $30.60 | Next Earning Date: | 08-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Seres Therapeutics Inc. (MCRB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Young Teresa L. | MCRB | See Remarks | May 15 '25 | Sell | $7.28 | 63 | $458.64 | 5,044 | |
| DesRosier Thomas | MCRB | Chief Legal Officer and EVP | May 15 '25 | Sell | $7.28 | 79 | $575.12 | 7,287 | |
| Shaff Eric D. | MCRB | CEO and President | May 15 '25 | Sell | $7.28 | 220 | $1,601.60 | 10,102 | |
| Henn Matthew R. | MCRB | See Remarks | May 15 '25 | Sell | $7.28 | 77 | $560.56 | 4,383 |
Latest Seres Therapeutics Inc. News
MCRB Breaking Stock News: Dive into MCRB Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Human Microbiome Market Forecasts Report 2025-2030: Key Insights for Navigating Emerging Opportunities
GlobeNewswire
25 days ago
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
Zacks
a month ago
Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?
MT Newswires
a month ago
Seres Therapeutics Shares Fall After Downgrade From Chardan
MT Newswires
a month ago
Chardan Downgrades Seres Therapeutics to Neutral From Buy, Adjusts Price Target to $6 From $25
Associated Press Finance
a month ago
Seres Therapeutics: Q1 Earnings Snapshot
GlobeNewswire
a month ago
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
2 months ago
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
Compare MCRB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MCRB Seres Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.